Skip to main content
SpringerLink
Log in

Dorsal Root Ganglion Disorders

  • Chapter
  • First Online:
Book cover Neuromuscular Disorders in Clinical Practice

Abstract

Disorders of the dorsal root ganglia are increasingly recognized as causes of sensory loss and ataxia. This chapter covers first the development, anatomy, chemistry, and physiology of the dorsal root ganglia. This is followed by discussions of the clinical manifestations, diagnosis, and management of disorders of the dorsal root ganglia. This includes paraneoplastic and immune-mediated nonmalignant inflammatory sensory polyganglionopathies as well as sensory ganglionopathy associated with Sjögren syndrome and toxic and nutritional ganglionopathies.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 229.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 299.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 449.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

CANOMAD:

Paraproteinemia chronic ataxic neuropathy ophthalmoplegia IgM paraprotein cold agglutinins disialosyl antibodies

CDDP:

cis-Diamminedichloroplatinum

CISP:

Chronic immune sensory polyradiculopathy

CSS:

Central sensory syndrome

HSAN:

Hereditary sensory and autonomic neuropathy

MISP:

Malignant inflammatory sensory polyganglionopathy

NISP:

Nonmalignant inflammatory sensory polyganglionopathy

POLG:

Polymerase gamma

SCLC:

Small cell lung carcinoma

References

  1. Adams F. The genuine works of Hippocrates. London: Sydenham Society; 1849. p. 76.

    Google Scholar 

  2. Stanley E. A case of disease in the posterior columns of the spinal cord. Med Chir Trans. 1840;5:80.

    Google Scholar 

  3. Todd RB. Cyclopaedia of anatomy and physiology, vol. III. London: Longman, Brown, Green, Longmans, and Roberts; 1839. p. 721.

    Google Scholar 

  4. Duchenne GBA. De l’ataxie locomotrice progressive. Arch Gen Med. 1858;1:641–52.

    Google Scholar 

  5. Gowers WR. A manual of diseases of the nervous system. Philadelphia: P. Blakiston, Son & Co; 1888. p 311.

    Google Scholar 

  6. Gowers WR. Multiple neuritis. Philadelphia: P. Blakiston, Son & Co; 1888. p. 108–19.

    Google Scholar 

  7. Weber FP, Hill TR. Complete degeneration of the posterior columns of the spinal cord with chronic polyneuritis in a case of widespread carcinomatous disease elsewhere. J Neurol Psychopathol. 1934;14:57–60.

    Google Scholar 

  8. Denny-Brown D. Primary sensory neuropathy with muscular changes associated with carcinoma. J Neurol Neurosurg Psychiatry. 1948;11:73–87.

    Article  PubMed  CAS  Google Scholar 

  9. Reid H, Fallon RJ. Bacterial infections. Adams JH, Duchen LW. Greenfield’s Neuropathology. 5th ed. New York: Oxford University Press; 1992. p. 302–34.

    Google Scholar 

  10. Dodgson MCH, Hoffman HL. Sensory neuropathy associated with carcinoma of the esophagus: report of a case. Ann Intern Med. 1953;38:130–5.

    Article  PubMed  CAS  Google Scholar 

  11. Heathfield KWG, Williams JRB. Peripheral neuropathy and myopathy associated with bronchogenic carcinoma. Brain. 1954;77:122–37.

    Article  PubMed  CAS  Google Scholar 

  12. Henson RA, Russell DS, Wilkinson M. Carcinomatous neuropathy and myopathy. A clinical and pathological study. Brain. 1954;77:82–121.

    Article  PubMed  CAS  Google Scholar 

  13. Gray KW, Woolf AL, Wright EA. Two cases of primary sensory neuropathy associated with carcinoma. Guy’s Hosp Rep. 1955;104:157–76.

    CAS  Google Scholar 

  14. Smith WT, Whitfield AGW. Malignant sensory neuropathy. Lancet. 1955;1:282–5.

    Article  Google Scholar 

  15. Murdoch WR, Walker RS. Carcinoma of the lung presenting as ataxia. Scott Med J. 1957;2:39–41.

    PubMed  CAS  Google Scholar 

  16. Bickerstaff ER. Carcinomatous sensory neuropathy associated with pin head-sized anaplastic carcinoma and plasma cell “­encephalitis”. Birmingham Med Rev. 1958;20:355–62.

    Google Scholar 

  17. Dyck PJ, Bailey AA, Olszewski J. Carcinomatous neuromyopathy: a case of sensory neuropathy and myopathy with onset three and one-half years before clinical recognition of the bronchogenic ­carcinoma. Can Med Assoc J. 1958;79:913–16.

    PubMed  CAS  Google Scholar 

  18. Croft PB, Henson RA, Urich H, Wilkinson PC. Sensory neuropathy with bronchial carcinoma: a study of four cases showing serological abnormalities. Brain. 1965;88:501–14.

    Article  PubMed  CAS  Google Scholar 

  19. Horwich MS, Cho L, Porro RS, Posner JB. Subacute sensory neuropathy: a remote effect of carcinoma. Ann Neurol. 1977;2:7–19.

    Article  PubMed  CAS  Google Scholar 

  20. Wilkinson PC. Serological findings in carcinomatous neuromyopathy. Lancet. 1965;1:1301–3.

    Google Scholar 

  21. Wartenberg R. Neuritis, sensory neuritis, neuralgia. A clinical study with review of the literature. New York: Oxford University Press; 1958. p. 444.

    Google Scholar 

  22. Martin CA. Polyradiculite postérieure ascendante a virus. Laval Med. 1946;11:387–92.

    PubMed  CAS  Google Scholar 

  23. Barré MJA. Syndrome sacré sensitivo-sensoriel, à évolution cyclique (d′après cinq cas). Rev Neurol (Paris). 1948;80:294–7.

    Google Scholar 

  24. Dyck PJ, Gutrecht JA, Bastron JA, Karnes WE, Dale AJD. Histologic and teased-fiber measurements of sural nerve in ­disorders of lower motor and primary sensory neurons. Mayo Clin Proc. 1968;43:81–123.

    PubMed  CAS  Google Scholar 

  25. Sterman AB, Schaumburg HH, Asbury AK. The acute sensory ­neuronopathy syndrome: a distinct clinical entity. Ann Neurol. 1980;7:354–8.

    Article  PubMed  CAS  Google Scholar 

  26. Kaufman MD, Hopkins LC, Hurwitz BJ. Progressive sensory neuropathy in patients without carcinoma: a disorder with distinctive clinical and electrophysiological findings. Ann Neurol. 1981;9:237–42.

    Article  PubMed  CAS  Google Scholar 

  27. Hayashi H, Tsubaki T. Enzymatic analysis of individual anterior horn cells in amyotrophic lateral sclerosis and Duchenne muscular dystrophy. J Neurol Sci. 1982;57:133–42.

    Article  PubMed  CAS  Google Scholar 

  28. Malinow K, Yannakakis GD, Glusman SM, Edlow DW, Griffin J, Pestronk A, et al. Subacute sensory neuronopathy secondary to dorsal root ganglionitis in primary Sjögren’s syndrome. Ann Neurol. 1986;20:535–7.

    Article  PubMed  CAS  Google Scholar 

  29. Mellgren SI, Conn DL, Stevens JC, Dyck PJ. Peripheral neuropathy in primary Sjögren’s syndrome. Neurology. 1989;39:390–4.

    Article  PubMed  CAS  Google Scholar 

  30. Griffin JW, Cornblath DR, Alexander E, Campbell J, Low PA, Bird S, et al. Ataxic sensory neuropathy and dorsal root ganglionitis associated with Sjögren’s syndrome. Ann Neurol. 1990;27:304–15.

    Article  PubMed  CAS  Google Scholar 

  31. Windebank AJ, Blexrud MD, Dyck PJ, Daube JR, Karnes JL. The syndrome of acute sensory neuropathy: clinical features and electrophysiologic and pathologic changes. Neurology. 1990;40:584–91.

    Article  PubMed  CAS  Google Scholar 

  32. Wintrobe MM, Mitchell DM, Kolb LC. Sensory neuron degeneration in vitamin deficiency. Degeneration of the posterior columns of the spinal cord, peripheral nerves, and dorsal root ganglion cells in young pigs fed a diet containing thiamin (B1) and riboflavin but otherwise deficient in vitamin B complex. J Exp Med. 1938;68:207–20.

    Article  PubMed  CAS  Google Scholar 

  33. Wintrobe MM, Miller Jr JL, Lisco H. The relation of diet to the occurrence of ataxia and degeneration in the nervous system of pigs. Bull Johns Hopkins Hosp. 1940;67:377–405.

    CAS  Google Scholar 

  34. Wintrobe MM, Miller MH, Follis Jr RH, Stein HJ, Mushatt C, Humphreys S. Sensory neuron degeneration in pigs. IV. Protection afforded by calcium pantothenate and pyridoxine. J Nutr. 1942;24:345–66.

    CAS  Google Scholar 

  35. Schaumburg H, Kaplan J, Windebank A, Vick N, Rasmus S, Pleasure D, et al. Sensory neuropathy from pyridoxine abuse-a new megavitamin syndrome. N Engl J Med. 1983;309:445–8.

    Article  PubMed  CAS  Google Scholar 

  36. Windebank AJ, Low PA, Blexrud MD, Schmelzer JD, Schaumburg HH. Pyridoxine neuropathy in rats: specific degeneration of sensory axons. Neurology. 1985;35:1617–22.

    Article  PubMed  CAS  Google Scholar 

  37. Luttrell CN, Mason KE. Vitamin E deficiency, dietary fat, and spinal cord lesions in the rat. Ann N Y Acad Sci. 1949;52:113–20.

    CAS  Google Scholar 

  38. Malamud N, Nelson MM, Evans HM. The effect of chronic vitamin E deficiency on the nervous system in the rat. Ann N Y Acad Sci. 1949;52:135–8.

    Google Scholar 

  39. Einarson L. Criticizing review of the concepts of the neuromuscular lesions in experimental vitamin E deficiency, preferably in adult rats. Acta Psychiatr Et Neurol Scandinavica. 1952;78:1–76.

    CAS  Google Scholar 

  40. Pentschew A, Schwarz K. Systemic axonal dystrophy in vitamin E deficient adult rats: with implication in human neuropathology. Acta Neuropathol (Berlin). 1962;1:313–34.

    Article  Google Scholar 

  41. Machlin LJ, Filipski R, Nelson J, Horn LR, Brin M. Effects of a prolonged vitamin E deficiency in the rat. J Nutr. 1977;107:1200–8.

    PubMed  CAS  Google Scholar 

  42. Rosenblum JL, Keating JP, Prensky AL, Nelson JS. A progressive neurologic syndrome in children with chronic liver disease. N Engl J Med. 1981;304:503–8.

    Article  PubMed  CAS  Google Scholar 

  43. Harding AE, Muller DPR, Thomas PK, Willison HJ. Spinocerebellar degeneration secondary to chronic intestinal malabsorption: a vitamin E deficiency syndrome. Ann Neurol. 1982;12:419–24.

    Article  PubMed  CAS  Google Scholar 

  44. Harding AE, Matthews S, Jones S, Ellis CJK, Booth IW, Muller DPR. Spinocerebellar degeneration associated with a selective defect of vitamin E absorption. N Engl J Med. 1985;313:32–5.

    Article  PubMed  CAS  Google Scholar 

  45. Von Hoff DD, Schilsky R, Reichert CM, Reddick RL, Rozencweig M, Young RC, et al. Toxic effects of cis-dichlorodiammineplatinum(II) in man. Cancer Treat Rep. 1979;63:1527–31.

    Google Scholar 

  46. Walsh TJ, Clark AW, Parhad IM, Green WR. Neurotoxic effects of cisplatin therapy. Arch Neurol. 1982;39:719–20.

    Article  PubMed  CAS  Google Scholar 

  47. Windebank AJ. Chemotherapeutic neuropathy. Curr Opin Neurol. 1999;12:565–71.

    Article  PubMed  CAS  Google Scholar 

  48. McDonald ES, Windebank AJ. Mechanisms of neurotoxic injury and cell death. Neurol Clin. 2000;18:525–40.

    Article  PubMed  CAS  Google Scholar 

  49. Windebank AJ. Peripheral neuropathy due to chemical and industrial exposure. In: Matthews WB, editor. Handbook of clinical ­neurology. Amsterdam: Elsevier Science Publishers; 1987. p. 263–92.

    Google Scholar 

  50. Ziller C, Le Douarin NM. The neural crest in nerve development. In: Dyck PJ, Thomas PK, Griffin JW, et al., editors. Peripheral ­neuropathy. 3rd ed. Philadelphia: W. B. Saunders Company; 1993. p. 230–42.

    Google Scholar 

  51. Bunge MB, Wood PM, Tynan LB, Bates ML, Sanes JR. Perineurium originates from fibroblasts: demonstration in vitro with a retroviral marker. Science. 1989;243:229–31.

    Article  PubMed  CAS  Google Scholar 

  52. Thomas PK, Ochoa J, Berthold C-H, et al. Microscopic anatomy of the peripheral nervous system. In: Dyck PJ, Thomas PK, Griffin JW, editors. Peripheral neuropathy. 3rd ed. Philadelphia: W. B. Saunders Company; 1993. p. 28–91.

    Google Scholar 

  53. Peters A, Palay SL, Webster HD. The cellular sheaths of neurons. Peters A, Palay SL, Webster HD. Fine structure of the nervous system: neurons and their supporting cells. 3 ed. New York: Oxford University Press; 1991. p. 212–72.

    Google Scholar 

  54. McManis PG, Schmelzer JD, Zollman PJ, Low PA. Blood flow and autoregulation in somatic and autonomic ganglia. Comparison with sciatic nerve. Brain. 1997;120:445–9.

    Article  PubMed  Google Scholar 

  55. Sasaki H, Schmelzer JD, Zollman PJ, Low PA. Neuropathology and blood flow of nerve, spinal roots and dorsal root ganglia in longstanding diabetic rats. Acta Neuropathol (Berlin). 1997;93:118–28.

    Article  CAS  Google Scholar 

  56. Parry GJ. Myelopathies affecting anterior horn cells. In: Dyck PJ, Thomas PK, Griffin JW, et al., editors. Peripheral neuropathy. 3rd ed. Philadelphia: W. B. Saunders Company; 1993. p. 887–98.

    Google Scholar 

  57. Lee KH, Chung K, Chung JM, Coggeshall RE. Correlation of cell body size, axon size, and signal conduction velocity for individually labelled dorsal root ganglion cells in the cat. J Comp Neurol. 1986;243:335–46.

    Article  PubMed  CAS  Google Scholar 

  58. Cajal SR. Histologie du système nerveux de l’homme et des vertébrés. Paris: Norbert Maloine; 1909.

    Google Scholar 

  59. Langford LA, Coggeshall RE. Branching of sensory axons in the peripheral nerve of the rat. J Comp Neurol. 1981;203:745–50.

    Article  PubMed  CAS  Google Scholar 

  60. Chung K, Coggeshall RE. The ratio of dorsal root ganglion cells to dorsal root axons in sacral segments of the cat. J Comp Neurol. 1984;225:24–30.

    Article  PubMed  CAS  Google Scholar 

  61. Gu Y, Chen Y, Zhang X, Li GW, Wang C, Huang LY. Neuronal soma-satellite glial cell interactions in sensory ganglia and the participation of purinergic receptors. Neuron Glia Biol. 2010;6(1):53–62.

    Article  PubMed  Google Scholar 

  62. Yaksh TL. The central pharmacology of primary afferents with emphasis on the disposition and role of primary afferent substance P. In: Yaksh TL, editor. Spinal afferent processing. New York: Plenum Press; 1986. p. 165–95.

    Chapter  Google Scholar 

  63. Curtis DR, Johnston GAR. Amino acid transmitters in the mammalian central nervous system. Rev Physiol. 1974;69:98–188.

    Google Scholar 

  64. Hokfelt T, Kellerth JO, Nilsson G, Pernow B. Experimental immunohistochemical studies on the localization and distribution of substance P in cat primary sensory neurons. Brain Res. 1975;100:235–52.

    Article  PubMed  CAS  Google Scholar 

  65. Yaksh TL, Abay EO, Go VL. Studies on the location and release of cholecystokinin and vasoactive intestinal peptide in rat and cat ­spinal cord. Brain Res. 1982;242:279–90.

    Article  PubMed  CAS  Google Scholar 

  66. Dalsgaard CJ, Vincent SR, Hokfelt T, Lundberg JM, Dahlstrom A, Schultzberg M, et al. Coexistence of cholecystokinin- and ­substance P-like peptides in neurons of the dorsal root ganglia of the rat. Neurosci Lett. 1982;33:159–63.

    Article  PubMed  CAS  Google Scholar 

  67. Hokfelt T, Johansson O, Ljungdahl A, Lundberg JM, Schultzberg M. Peptidergic neurones. Nature. 1980;284:515–21.

    Article  PubMed  CAS  Google Scholar 

  68. Panula P, Yang HY, Costa E. Neuronal location of the bombesin-like immunoreactivity in the central nervous system of the rat. Regul Pept. 1982;4:275–83.

    Article  PubMed  CAS  Google Scholar 

  69. Bergman E, Carlsson K, Liljeborg A, Manders E, Hokfelt T, Ulfhake B. Neuropeptides, nitric oxide synthase and GAP-43 in B4-binding and RT97 immunoreactive primary sensory neurons: normal distribution pattern and changes after peripheral nerve transection and aging. Brain Res. 1999;832:63–83.

    Article  PubMed  CAS  Google Scholar 

  70. Koltzenburg M. The changing sensitivity in the life of the nociceptor. Pain. 1999;82 Suppl 6Suppl 6:S93–102.

    Article  Google Scholar 

  71. Apfel SC. Neurotrophic factors in peripheral neuropathies: therapeutic implications. Brain Pathol. 1999;9:393–413.

    Article  PubMed  CAS  Google Scholar 

  72. Hokfelt T, Broberger C, Xu ZQ, Sergeyev V, Ubink R, Diez M. Neuropeptides–an overview. Neuropharmacology. 2000;39:1337–56.

    Article  PubMed  CAS  Google Scholar 

  73. Kernie SG, Parada LF. The molecular basis for understanding neurotrophins and their relevance to neurologic disease. Arch Neurol. 2000;57:654–7.

    Article  PubMed  CAS  Google Scholar 

  74. Devor M. Unexplained peculiarities of the dorsal root ganglion. Pain. 1999;82 Suppl 6Suppl 6:S27–35.

    Article  Google Scholar 

  75. Cervero F. Dorsal horn neurons and their sensory inputs. In: Yaksh TL, editor. Spinal afferent processing. New York: Plenum Press; 1986. p. 197–216.

    Chapter  Google Scholar 

  76. Brown AG, Iggo A. A quantitative study of cutaneous receptors and afferent fibres in the cat and rabbit. J Physiol (Lond). 1967;193:707.

    CAS  Google Scholar 

  77. Light AR, Perl ER. Spinal termination of functionally identified primary afferent neurons with slowly conducting myelinated fibers. J Comp Neurol. 1979;186:133–50.

    Article  PubMed  CAS  Google Scholar 

  78. Iggo A. Cutaneous thermoreceptors in primates and sub-primates. J Physiol (Lond). 1969;200:403–30.

    CAS  Google Scholar 

  79. Brown AG. Organisation in the spinal cord. Heidelberg: Springer; 1981.

    Book  Google Scholar 

  80. Cervero F, Connell LA. Fine afferent fibers from viscera do not terminate in the substantia gelatinosa of the thoracic spinal cord. Brain Res. 1984;294:370–4.

    Article  PubMed  CAS  Google Scholar 

  81. Price DD. The question of how the dorsal horn encodes sensory information. In: Yaksh TL, editor. Spinal afferent processing. New York: Plenum Press; 1986. p. 445–504.

    Chapter  Google Scholar 

  82. Gilliatt RW, Le Quesne PM, Logue V, Sumner AJ. Wasting of the hand associated with a cervical rib or band. J Neurol Neurosurg Psychiatry. 1970;33:615–24.

    Article  PubMed  CAS  Google Scholar 

  83. Evans BA. Nerve action potentials. In: Daube JR, editor. Clinical neurophysiology. Philadelphia: FA Davis Company; 1996. p. 147–56.

    Google Scholar 

  84. Dyck PJ, Karnes J, O’Brien PC, et al. Detection thresholds of cutaneous sensation in humans. In: Dyck PJ, Thomas PK, Griffin JW, et al., editors. Peripheral neuropathy. 3rd ed. Philadelphia: W. B. Saunders Company; 1993. p. 706–28.

    Google Scholar 

  85. Apfel SC, Kessler JA, Adornato BT, Litchy WJ, Sanders C, Rask CA, et al. Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy. Neurology. 1998;51:695–702.

    Article  PubMed  CAS  Google Scholar 

  86. Dyck PJ, O’Brien PC. Quantitative sensation testing in epidemiological and therapeutic studies of peripheral neuropathy. Muscle Nerve. 1999;22:659–62.

    Article  PubMed  CAS  Google Scholar 

  87. McArthur JC, Yiannoutsos C, Simpson DM, Adornato BT, Singer EJ, Hollander H, et al. A phase II trial of nerve growth factor for sensory neuropathy associated with HIV infection. AIDS Clinical Trials Group Team 291. Neurology. 2000;54:1080–8.

    Article  PubMed  CAS  Google Scholar 

  88. Wang AK, Gillen DA, Dyck PJ. Effect of simple analgesics on quantitative sensation test threshold. Neurology. 1999;53:1865–7.

    Article  PubMed  CAS  Google Scholar 

  89. Harper CM Jr. Somatosensory evoked potentials. Daube JR. Clinical neurophysiology. Philadelphia: FA Davis Company; 1996. p. 157–64.

    Google Scholar 

  90. Dalmau J, Graus F, Rosenblum MK, Posner JB. Anti-Hu-associated paraneoplastic encephalomyelitis/sensory neuronopathy. A clinical study of 71 patients. Medicine (Baltimore). 1992;71:59–72.

    CAS  Google Scholar 

  91. Pieret F, Sindic CJ, Chalon MP, Warny M, Bolyn S, Dehaene I, et al. The anti-Hu syndrome: a clinical and immunological study of 7 cases. Acta Neurol Belg. 1996;96:108–16.

    PubMed  CAS  Google Scholar 

  92. Rowland LP, Schneck SA. Neuromuscular disorders associated with malignant neoplastic disease. J Chronic Dis. 1963;16:777–95.

    Article  PubMed  CAS  Google Scholar 

  93. Chalk CH, Windebank AJ, Kimmel DW, McManis PG. The distinctive clinical features of paraneoplastic sensory neuronopathy. Can J Neurol Sci. 1992;19:346–51.

    PubMed  CAS  Google Scholar 

  94. Wyburn-Mason R. Bronchial carcinoma presenting as polyneuritis. Lancet. 1948;1:203.

    Article  PubMed  CAS  Google Scholar 

  95. McCaughey WTE, Millar JHD. Nervous degeneration in malignant disease. Lancet. 1955;2:365–6.

    Article  Google Scholar 

  96. Uelinger UE. Sensorische und motorische neuropathie bei lungenkarzinom. Schweiz Med Wochenschr. 1957;87:1580.

    Google Scholar 

  97. Vega F, Graus F, Chen QM, Poisson M, Schuller E, Delattre JY. Intrathecal synthesis of the anti-Hu antibody in patients with paraneoplastic encephalomyelitis or sensory neuronopathy: clinical- immunologic correlation. Neurology. 1994;44:2145–7.

    Article  PubMed  CAS  Google Scholar 

  98. Castleman B, Kibbie B. Case records of the Massachusetts General Hospital. N Engl J Med. 1960;263:804.

    Article  Google Scholar 

  99. Henson RA, Hoffman HL, Urich H. Encephalomyelitis with carcinoma. Brain. 1965;88:449–64.

    Article  PubMed  CAS  Google Scholar 

  100. Croft PB, Urich H, Wilkinson M. Peripheral neuropathy of sensorimotor type associated with malignant disease. Brain. 1967;90:31–66.

    Article  PubMed  CAS  Google Scholar 

  101. Vick N, Schulman S, Dau P. Carcinomatous cerebellar degeneration, encephalomyelitis, and sensory neuropathy (radiculitis). Report of a case incorporating both purely degenerative and intense inflammatory changes, with special prominence of the latter in the putamen. Neurology. 1969;19:425–41.

    Article  PubMed  CAS  Google Scholar 

  102. Maitland CG, Scherokman BJ, Schiffman J, Harlan JW, Galdi AP. Paraneoplastic tonic pupils. J Clin Neuro-ophthalmol. 1985;5:99–104.

    CAS  Google Scholar 

  103. Kimmel DW, O’Neill BP, Lennon VA. Subacute sensory ­neuronopathy associated with small cell lung carcinoma: ­diagnosis aided by autoimmune serology. Mayo Clin Proc. 1988;63:29–32.

    Article  PubMed  CAS  Google Scholar 

  104. Gabriel CM, Gregson NA, Hughes RAC. Sensory neuropathy and anti-Hu antibodies in a patient with seminoma. Eur J Neurol. 1996;3:471–4.

    Article  Google Scholar 

  105. Pourmand R, Maybury BG. AAEM case report #31: ­paraneoplastic sensory neuronopathy. Muscle Nerve. 1996;19:1517–22.

    Article  PubMed  CAS  Google Scholar 

  106. Oh SJ, Dropcho EJ, Claussen GC. Anti-Hu-associated paraneoplastic sensory neuropathy responding to early aggressive immunotherapy: report of two cases and review of literature. Muscle Nerve. 1997;20:1576–82.

    Article  PubMed  CAS  Google Scholar 

  107. Wanschitz J, Hainfellner J-A, Kristoferitsch W, Drlicek M, Budka H. Ganglionitis in paraneoplastic subacute sensory neuronopathy: a morphologic study. Neurology. 1997;49:1156–9.

    Article  PubMed  CAS  Google Scholar 

  108. Casas Parera I, Fischman D, Paz L, Lehkuniec E, Muchnik S. Paraneoplastic neuropathy with positive anti-Hu. Medicina (Buenos Aires). 1998;58:197–201.

    CAS  Google Scholar 

  109. Antoine JC, Absi L, Honnorat J, Boulesteix JM, de Brouker T, Vial C, et al. Antiamphiphysin antibodies are associated with ­various paraneoplastic neurological syndromes and tumors. Arch Neurol. 1999;56:172–7.

    Article  PubMed  CAS  Google Scholar 

  110. Antoine JC, Mosnier JF, Absi L, Convers P, Honnorat J, Michel D. Carcinoma associated paraneoplastic peripheral neuropathies in patients with and without anti-onconeural antibodies. J Neurol Neurosurg Psychiatry. 1999;67:7–14.

    Article  PubMed  CAS  Google Scholar 

  111. Lhermitte F, Gray F, Lyon-Caen O, Pertuiset BF, Bernard P. Paralysis of digestive tract with lesions of myenteric plexuses. A new paraneoplastic syndrome (author’s transl). Rev Neurol (Paris). 1980;136:825–36.

    CAS  Google Scholar 

  112. Henson RA, Urich H. Cancer and the nervous system. Boston: Blackwell Scientific Publications; 1982. p. 378–80.

    Google Scholar 

  113. Brunet P, Schadeck B, Moriceau M. Subacute sensory neuropathy with remission: an association with lymphoma. J Neurol Neurosurg Psychiatry. 1983;46:99–100.

    Article  PubMed  CAS  Google Scholar 

  114. Sagar HJ, Read DJ. Subacute sensory neuropathy with remission: an association with lymphoma. J Neurol Neurosurg Psychiatry. 1982;45:83–5.

    Article  PubMed  CAS  Google Scholar 

  115. Scully RE, Mark EJ, McNeely F. Case records of the Massachusetts General Hospital. N Engl J Med. 1990;322:531.

    Article  Google Scholar 

  116. Ichimura M, Yamamoto M, Kobayashi Y, Kawakami O, Niimi Y, Hattori N, et al. Tissue distribution of pathological lesions and Hu antigen expression in paraneoplastic sensory neuronopathy. Acta Neuropathol (Berlin). 1998;95:641–8.

    Article  CAS  Google Scholar 

  117. Smith BE. Inflammatory sensory polyganglionopathies. Neurol Clin. 1992;10:735–59.

    PubMed  CAS  Google Scholar 

  118. Titulaer MJ, Soffietti R, Dalmau J, Gilhus NE, Giometto B, Graus F, et al. European Federation of Neurological Societies. Screening for tumours in paraneoplastic syndromes: report of an EFNS task force. Eur J Neurol. 2011;18(1):19–e3.

    Article  PubMed  CAS  Google Scholar 

  119. Braik T, Evans AT, Telfer M, McDunn S. Paraneoplastic neurological syndromes: unusual presentations of cancer. A practical review. Am J Med Sci. 2010;340(4):301–8.

    Article  PubMed  Google Scholar 

  120. Vedeler CA, Antoine JC, Giometto B, Graus F, Grisold W, Hart IK, et al. Paraneoplastic Neurological Syndrome Euronetwork. Management of paraneoplastic neurological syndromes: report of an EFNS Task Force. Eur J Neurol. 2006;13(7):682–90.

    Article  PubMed  CAS  Google Scholar 

  121. Bi WL, Bannykh SI, Martel M, Baehring JM. Paraneoplastic ­subacute sensory neuronopathy secondary to a malignant mixed Müllerian tumor. Obstet Gynecol. 2006;107(2 Pt 2):504–6.

    Article  PubMed  Google Scholar 

  122. Schilstra A, van Tuijl JH, van Suylen RJ, Faber CG, ten Velde GP. Unclassified rhabdomyosarcoma in a patient with anti-Hu ­syndrome. Acta Clin Belg. 2005;60(5):248–51.

    PubMed  CAS  Google Scholar 

  123. Gazic B, Pisem J, Dolenc-Groselj L, Popovic M. Paraneoplastic encephalomyelitis/sensory motor peripheral neuropathy – an autopsy case study. Folia Neuropathol. 2005;43(2):113–17.

    PubMed  Google Scholar 

  124. Oh SJ, Gurtekin Y, Dropcho EJ, King P, Claussen GC. Anti-Hu antibody neuropathy: a clinical, electrophysiological, and pathological study. Clin Neurophysiol. 2005;116(1):28–34.

    Article  PubMed  Google Scholar 

  125. Kuntzer T, Antoine JC, Steck AJ. Clinical features and pathophysiological basis of sensory neuronopathies (ganglionopathies). [Review]. Muscle Nerve. 2004;30(3):255–68.

    Article  PubMed  Google Scholar 

  126. Storstein A, Monstad SE, Nakkestad HL, Husebye ES, Vedeler CA. Paraneoplastic antibodies against HuD detected by a sensitive radiobinding assay. J Neurol. 2004;251(2):197–203.

    Article  PubMed  CAS  Google Scholar 

  127. Kiylioglu N, Meydan N, Barutca S, Akyol A. Sub-acute sensory neuronopathy as a preceding sign of recurrence in colon carcinoma. Int J Gastrointest Cancer. 2003;34(2–3):135–7.

    Article  PubMed  Google Scholar 

  128. Benyahia B, Amoura Z, Rousseau A, Le Clanche C, Carpentier A, Piette JC, et al. Paraneoplastic antineuronal antibodies in patients with systemic autoimmune diseases. J Neurooncol. 2003;62(3):349–51.

    Article  PubMed  CAS  Google Scholar 

  129. Camdessanche JP, Antoine JC, Honnorat J, Vial C, Petiot P, Convers P, et al. Paraneoplastic peripheral neuropathy associated with anti-Hu antibodies. A clinical and electrophysiological study of 20 patients. Brain. 2002;125(Pt 1):166–75.

    Article  PubMed  Google Scholar 

  130. Antoine JC, Honnorat J, Camdessanche JP, Magistris M, Absi L, Mosnier JF, et al. Paraneoplastic anti-CV2 antibodies react with peripheral nerve and are associated with a mixed axonal and demyelinating peripheral neuropathy. Ann Neurol. 2001;49(2):214–21.

    Article  PubMed  CAS  Google Scholar 

  131. Graus F, Bonaventura I, Uchuya M, Valls-Solé J, Reñé R, Leger JM, et al. Indolent anti-Hu-associated paraneoplastic sensory neuropathy. Neurology. 1994;44:2258–61.

    Article  PubMed  CAS  Google Scholar 

  132. Lucchinetti CF, Kimmel DW, Lennon VA. Paraneoplastic and oncologic profiles of patients seropositive for type 1 antineuronal nuclear autoantibodies. Neurology. 1998;50(3):652–7.

    Article  PubMed  CAS  Google Scholar 

  133. Dalmau J, Gultekin HS, Posner JB. Paraneoplastic neurologic syndromes: pathogenesis and physiopathology. Brain Pathol. 1999;9:275–84.

    Article  PubMed  CAS  Google Scholar 

  134. Tanaka K, Tanaka M, Inuzuka T, Nakano R, Tsuji S. Cytotoxic T, lymphocyte-mediated cell death in paraneoplastic sensory neuronopathy with anti-Hu antibody. J Neurol Sci. 1999;163:159.

    Article  PubMed  CAS  Google Scholar 

  135. Benyahia B, Liblau R, Merle-Beral H, Tourani JM, Dalmau J, Delattre JY. Cell-mediated autoimmunity in paraneoplastic neurological syndromes with anti-Hu antibodies. Ann Neurol. 1999;45:162–7.

    Article  PubMed  CAS  Google Scholar 

  136. Plonquet A, Gherardi RK, Creange A, Antoine JC, Benyahia B, Grisold W, et al. Oligoclonal T-cells in blood and target tissues of patients with anti-Hu syndrome. J Neuroimmunol. 2002;122:100–5.

    Article  PubMed  CAS  Google Scholar 

  137. Ohnishi A, Ogawa M. Preferential loss of large lumbar primary sensory neurons in carcinomatous sensory neuropathy. Ann Neurol. 1986;20:102–4.

    Article  PubMed  CAS  Google Scholar 

  138. Anderson NE, Rosenblum MK, Graus F, Wiley RG, Posner JB. Autoantibodies in paraneoplastic syndromes associated with small- cell lung cancer. Neurology. 1988;38:1391–8.

    Article  PubMed  CAS  Google Scholar 

  139. Graus F, Cordon-Cardo C, Posner JB. Neuronal antinuclear antibody in sensory neuronopathy from lung cancer. Neurology. 1985;35:538–43.

    Article  PubMed  CAS  Google Scholar 

  140. Lennon VA, Sas DF, Busk MF, Scheithauer B, Malagelada J-R, Camilleri M, et al. Enteric neuronal autoantibodies in pseudoobstruction with small-cell lung carcinoma. Gastroenterology. 1991;100:137–42.

    PubMed  CAS  Google Scholar 

  141. Pestronk A, Li F, Griffin J, Feldman EL, Cornblath D, Trotter J, et al. Polyneuropathy syndromes associated with serum antibodies to sulfatide and myelin-associated glycoprotein. Neurology. 1991;41:357–62.

    Article  PubMed  CAS  Google Scholar 

  142. Auger RG, Windebank AJ, Lucchinetti CF, Chalk CH. Role of the blink reflex in the evaluation of sensory neuronopathy. Neurology. 1999;53:407–8.

    Article  PubMed  CAS  Google Scholar 

  143. Lauria G, Pareyson D, Grisoli M, Sghirlanzoni A. Clinical and magnetic resonance imaging findings in chronic sensory ganglionopathies. Ann Neurol. 2000;47(1):104–9.

    Article  PubMed  CAS  Google Scholar 

  144. Antoine JC, Cinotti L, Tilikete C, Bouhour F, Camdessanche JP, Confavreux C, et al. [18F]Fluorodeoxyglucose positron emission tomography in the diagnosis of cancer in patients with paraneoplastic neurological syndrome and anti-Hu antibodies. Ann Neurol. 2000;48:105–8.

    Article  PubMed  CAS  Google Scholar 

  145. Linke R, Schroeder M, Helmberger T, Voltz R. Antibody-positive paraneoplastic neurologic syndromes: value of CT and PET for tumor diagnosis. Neurology. 2004;63:282–6.

    Article  PubMed  Google Scholar 

  146. Younes-Mhenni S, Janier MF, Cinotti L, et al. FDG-PET improves tumour detection in patients with paraneoplastic neurological ­syndromes. Brain. 2004;127:2331–8.

    Article  PubMed  CAS  Google Scholar 

  147. Scaravilli F, An SF, Groves M, Thom M. The neuropathology of paraneoplastic syndromes. Brain Pathol. 1999;9(2):251–60.

    Article  PubMed  CAS  Google Scholar 

  148. Krishnamurthy S, Schuffler MD. Pathology of neuromuscular ­disorders of the small intestine and colon. Gastroenterology. 1987;93:610.

    PubMed  CAS  Google Scholar 

  149. Chinn JS, Schuffler D. Paraneoplastic visceral neuropathy as a cause of severe gastrointestinal motor dysfunction. Gastroen­terology. 1988;95:1279.

    PubMed  CAS  Google Scholar 

  150. Hughes RAC, Britton T, Richards M. Effects of lymphoma on the peripheral nervous system. J R Soc Med. 1994;87:526.

    PubMed  CAS  Google Scholar 

  151. Uchuya M, Graus F, Vega F, Rene R, Delattre JY. Intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with antineuronal autoantibodies. J Neurol Neurosurg Psychiatry. 1996;60(4):388–92.

    Article  PubMed  CAS  Google Scholar 

  152. Keime-Guibert F, Graus F, Fleury A, Rene R, Honnorat J, Broet P, et al. Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone. J Neurol Neurosurg Psychiatry. 2000;68(4):479–82.

    Article  PubMed  CAS  Google Scholar 

  153. Graus F, Keime-Guibert F, Reňe R, et al. Anti-Hu associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain. 2001;124:1138–48.

    Article  PubMed  CAS  Google Scholar 

  154. Dalakas MC. Chronic idiopathic ataxic neuropathy. Ann Neurol. 1986;19:545–54.

    Article  PubMed  CAS  Google Scholar 

  155. Cooke WT, Smith WT. Neurological disorders associated with adult coeliac disease. Brain. 1966;89(4):683–722.

    Article  PubMed  CAS  Google Scholar 

  156. Hull RG, Morgan SH, Harding AE, Hughes GR. Sjogren’s ­syndrome presenting as a severe sensory neuropathy including involvement of the trigeminal nerve. Br J Rheumatol. 1984;23(4):301–3.

    Article  PubMed  CAS  Google Scholar 

  157. Mitsumoto H, Wilbourn AJ, Massarweh W. Acquired “pure” ­sensory polyneuropathy (APSP): unique clinical features in 30 patients. Neurology. 1985;35:295.

    Google Scholar 

  158. Kennett RP, Harding AE. Peripheral neuropathy associated with the sicca syndrome. J Neurol Neurosurg Psychiatry. 1986;49(1):90–2.

    Article  PubMed  CAS  Google Scholar 

  159. Hankey GJ, Gubbay SS. Peripheral neuropathy associated with sicca syndrome. J Neurol Neurosurg Psychiatry. 1987;50(8):1085–6.

    Article  PubMed  CAS  Google Scholar 

  160. Laloux P, Brucher JM, Guerit JM, Sindic CJ, Laterre EC. Subacute sensory neuronopathy associated with Sjogren’s sicca syndrome. J Neurol. 1988;235(6):352–4.

    Article  PubMed  CAS  Google Scholar 

  161. Knazan M, Bohlega S, Berry K, Eisen A. Acute sensory ­neuronopathy with preserved SEPs and long-latency reflexes. Muscle Nerve. 1990;13(5):381–4.

    Article  PubMed  CAS  Google Scholar 

  162. Sinnreich M, Klein CJ, Daube JR, Engelstad J, Spinner RJ, Dyck PJB. Chronic immune sensory polyradiculopathy. Neurology. 2004;63:1662–9.

    Article  PubMed  CAS  Google Scholar 

  163. Rubin DI, Daube JR. Subacute sensory neuropathy associated with Epstein-Barr virus. Muscle Nerve. 1999;22(11):1607–10.

    Article  PubMed  CAS  Google Scholar 

  164. Gilpin SF, Moersch FF, Kernohan JW. Polyneuritis: a clinical and pathologic study of a special group of cases frequently referred to as instances of neuronitis. Arch Neurol. 1936;35:937–63.

    Article  Google Scholar 

  165. Richter RB. The ataxic form of polyradiculoneuritis (Landry-Guillain-Barre syndrome): clinical and pathological observations. J Neuropathol Exp Neurol. 1962;21:171–84.

    Article  PubMed  CAS  Google Scholar 

  166. Sherman WH, Latov N, Hays AP, Takatsu M, Nemni R, Galassi G, et al. Monoclonal IgM k antibody precipitating with chondroitin sulfate C from patients with axonal polyneuropathy and epidermolysis. Neurology. 1983;33:192–201.

    Article  PubMed  CAS  Google Scholar 

  167. Hainfellner JA, Kristoferitsch W, Lassmann H, Bernheimer H, Neisser A, Drlicek M, et al. T cell-mediated ganglionitis associated with acute sensory neuronopathy. Ann Neurol. 1996;39:543–7.

    Article  PubMed  CAS  Google Scholar 

  168. Gherardi RK, Farcet JP, Creange A, Claudepierre P, Malapert D, Authier FJ, et al. Dominant T-cell clones of unknown significance in patients with idiopathic sensory neuropathies. Neurology. 1998;51(2):384–9.

    Article  PubMed  CAS  Google Scholar 

  169. Cornblath DR, McArthur JC, Kennedy PGE, Witte AS, Griffin JW. Inflammatory demyelinating peripheral neuropathies associated with human T-cell lymphotropic virus type III infection. Ann Neurol. 1987;21:32–40.

    Article  PubMed  CAS  Google Scholar 

  170. Arnason BGW et al. Acute inflammatory demyelinating polyradiculoneuropathies. In: Dyck PJ, Thomas PK, Lambert EH, ­editors. Peripheral neuropathy. 1st ed. Philadelphia: W. B. Saunders Company; 1984. p. 2050–100.

    Google Scholar 

  171. Dyck PJ, Lambert EH, Nichols PC. Quantitative measurement of sensation related to compound action potential and number and size of myelinated and unmyelinated fibers in health, Friedreich’s ataxia, hereditary sensory neuropathy, and tabes dorsalis. Cobb WA. Amsterdam: Elsevier Publishing Co.; 1972. p. 83.

    Google Scholar 

  172. Nemni R, Camerlingo M, Fazio R, Casto L, Quattrini A, Mamoli D, et al. Serum antibodies to Purkinje cells and dorsal root ganglia neurons in sensory neuronopathy without malignancy. Ann Neurol. 1993;34:848–54.

    Article  PubMed  CAS  Google Scholar 

  173. Briellmann RS, Sturzenegger M, Gerber HA, Schaffner T, Hess CW. Autoantibody-associated sensory neuronopathy and ­intestinal pseudo- obstruction without detectable neoplasia. Eur Neurol. 1996;36(6):369–73.

    Article  PubMed  CAS  Google Scholar 

  174. Hadjivassiliou M, Rao DG, Wharton SB, et al. Sensory ganglionopathy due to gluten sensitivity. Neurology. 2010;75:1003–8.

    Article  PubMed  CAS  Google Scholar 

  175. Conrad B, Benecke R. How valid is the distal sensory nerve action potential for differentiating between radicular and non-radicular nerve lesions? Acta Neurol Scand. 1979;60:122.

    Google Scholar 

  176. Yasuda T, Sobue G, Hirose Y, Mimura M, Yanagi T. MR of acute autonomic and sensory neuropathy. Am J Neuroradiol. 1994;15(1):114–15.

    PubMed  CAS  Google Scholar 

  177. Ross AT, Tinker JH. Anesthesia risk. In: Miller RD, editor. Anesthesia. New York: Churchill Livingstone; 1990. p. 715.

    Google Scholar 

  178. Chen WH, Yeh JH, Chiu HG. Plasmapheresis in the treatment of ataxic sensory neuropathy associated with Sjogren’s syndrome. Eur Neurol. 2001;45:270–4.

    Article  PubMed  Google Scholar 

  179. Takahashi Y, Takata T, Hoshimo M, Sakurai M, Kanazawa I. Benefit of IVIG for long-standing ataxic sensory neuronopathy with Sjogren’s syndrome. Neurology. 2003;60:503–5.

    Article  PubMed  CAS  Google Scholar 

  180. Caroyer JM, Manto MU, Steinfeld SD. Severe sensory neuronopathy responsive to infliximab in primary Sjogren’s syndrome. Neurology. 2002;59:1113–14.

    Article  PubMed  Google Scholar 

  181. Behina A, Psimarasb D, Hoang-Xuanb K, Leger JM. Neuropathies in the context of malignancies. Curr Opin Neurol. 2008;21:534–9.

    Article  CAS  Google Scholar 

  182. Yardley DE. Proactive management of adverse events maintains the clinical benefit of ixabepilone. Oncologist. 2009;14:448–55.

    Article  PubMed  CAS  Google Scholar 

  183. Reed E, Dabholkar M, Chabner BA. Platinum analogues. In: Chabner BA, Longo DL, editors. Cancer chemotherapy and biotherapy: principles and practice. 2nd ed. Philadelphia: Lippincott-Raven Publishers; 1996. p. 357–78.

    Google Scholar 

  184. Berman IJ, Mann MP. Seizures and transient cortical blindness associated with cis-platinum(II) diamminedichloride (PDD) ­therapy in a thirty-year-old man. Cancer. 1980;45:764–6.

    Article  PubMed  CAS  Google Scholar 

  185. Mead GM, Arnold AM, Green JA, Macbeth FR, Williams CJ, Whitehouse JM. Epileptic seizures associated with cisplatin administration. Cancer Treat Rep. 1982;66:1719–22.

    PubMed  CAS  Google Scholar 

  186. Krarup-Hansen A, Fugleholm K, Helweg-Larsen S, Hauge EN, Schmalbruch H, Trojaborg W, et al. Examination of distal involvement in cisplatin-induced neuropathy in man. An electrophysiological and histological study with particular reference to touch receptor function. Brain. 1993;116:1017–41.

    Article  PubMed  Google Scholar 

  187. Thompson SW, Davis LE, Kornfeld M, Hilgers RD, Standefer JC. Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies. Cancer. 1984;54:1269–75.

    Article  PubMed  CAS  Google Scholar 

  188. Gregg RW, Molepo JM, Monpetit VJA, Mikael NZ, Redmond D, Gadia M, et al. Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity. J Clin Oncol. 1992;10:795–803.

    PubMed  CAS  Google Scholar 

  189. Cowan JD, Kies MS, Roth JL, Joyce RP. Nerve conduction studies in patients treated with cis-diamminedichloroplatinum(II): a preliminary report. Cancer Treat Rep. 1980;64:1119–22.

    PubMed  CAS  Google Scholar 

  190. Cavaletti G, Bogliun G, Marzorati L, Tredici G, Colombo N, Parma G, et al. Long-term peripheral neurotoxicity of cisplatin in patients with successfully treated epithelial ovarian cancer. Anticancer Res. 1994;14:1287–92.

    PubMed  CAS  Google Scholar 

  191. Krarup-Hansen A, Helweg-Larsen S, Schmalbruch H, et al. Neuronal involvement in cisplatin neuropathy: prospective clinical and neurophysiological studies. Brain. 2007;130:1076–88.

    Article  PubMed  CAS  Google Scholar 

  192. Rosenfeld CS, Broder LE. Cisplatin-induced autonomic neuropathy. Cancer Treat Rep. 1984;68:659–60.

    PubMed  CAS  Google Scholar 

  193. Vandertop WP, de Vries WB, Notermans NC, Nijsen MJMA, de Wildt DJ, Tulleken CAF, et al. Cisplatin-induced autonomic neuropathy: does it really exist? J Neuro-oncol. 1996;27(1):53–60.

    Article  CAS  Google Scholar 

  194. Roelofs RI, Hrushesky W, Rogin J, Rosenberg L. Peripheral ­sensory neuropathy and cisplatin chemotherapy. Neurology. 1984;34:934–8.

    Article  PubMed  CAS  Google Scholar 

  195. Apfel SC, Arezzo JC, Lipson L, Kessler JA. Nerve growth factor prevents experimental cisplatin neuropathy. Ann Neurol. 1992;31:76–80.

    Article  PubMed  CAS  Google Scholar 

  196. Hamers FPT, Brakkee JH, Cavalletti E, Tedeschi M, Marmonti L, Pezzoni G, et al. Reduced glutathione protects against cisplatin-induced neurotoxicity in rats. Cancer Res. 1993;53:544–9.

    PubMed  CAS  Google Scholar 

  197. Cavaletti G, Minoia C, Schieppati M, Tredici G. Protective effects of glutathione on cisplatin neurotoxicity in rats. Int J Radiat Oncol Biol Phys. 1994;29:771–6.

    Article  PubMed  CAS  Google Scholar 

  198. Gerritsen van der Hoop R, Hamers FPT, Neijt JP, Veldman H, Gispen WH, Jennekens FGI. Protection against cisplatin induced neurotoxicity by ORG 2766: histological and electrophysiological evidence. J Neurol Sci. 1994;126:109–15.

    Article  PubMed  CAS  Google Scholar 

  199. Cece R, Petruccioli MG, Cavaletti G, Barajon I, Tredici G. An ultrastructural study of neuronal changes in dorsal root ganglia (DRG) of rats after chronic cisplatin administrations. Histol Histopathol. 1995;10:837–45.

    PubMed  CAS  Google Scholar 

  200. Tomiwa K, Nolan C, Cavanagh JB. The effects of cisplatin on rat spinal ganglia: a study by light and electron microscopy and by morphometry. Acta Neuropathol (Berlin). 1986;69:295–308.

    Article  CAS  Google Scholar 

  201. Cavaletti G, Tredici G, Marmiroli P, Fabbrica D, Braga M. Off-treatment course of cisplatin-induced dorsal root ganglia neuronopathy in rats. In Vivo. 1994;8:313–16.

    PubMed  CAS  Google Scholar 

  202. Barajon I, Bersani M, Quartu M, Del Fiacco M, Cavaletti G, Holst JJ, et al. Neuropeptides and morphological changes in cisplatin-induced dorsal root ganglion neuronopathy. Exp Neurol. 1996;138:93–104.

    Article  PubMed  CAS  Google Scholar 

  203. Terheggen PMAB, Gerritsen van der Hoop R, Floot BGJ, Gispen WH. Cellular distribution of cis-diamminedichloroplatinum(II)–DNA binding in rat dorsal root spinal ganglia: effect of the neuroprotecting peptide ORG.2766. Toxicol Appl Pharmacol. 1989;99:334–43.

    Article  PubMed  CAS  Google Scholar 

  204. Meijer C, de Vries EGE, Marmiroli P, Tredici G, Frattola L, Cavaletti G. Cisplatin-induced DNA-platination in experimental dorsal root ganglia neuronopathy. Neurotoxicology. 1999;20(6):883–7.

    PubMed  CAS  Google Scholar 

  205. Gill JS, Windebank AJ. Cisplatin-induced apoptosis in rat dorsal root ganglion neurons is associated with attempted entry into the cell cycle. J Clin Invest. 1998;101:2842–50.

    Article  PubMed  CAS  Google Scholar 

  206. Fu KK, Kai EFY, Leung CK. Cisplatin neuropathy: a prospective clinical and electrophysiological study in Chinese patients with ovarian carcinoma. J Clin Pharm Ther. 1995;20:167–72.

    Article  PubMed  CAS  Google Scholar 

  207. McKeage MJ. Comparative adverse effect profiles of platinum drugs. Drug Saf. 1995;13:228–44.

    Article  PubMed  CAS  Google Scholar 

  208. Ozols RF, Ostchega Y, Myers CE, Young RC. High-dose cisplatin in hypertonic saline in refractory ovarian cancer. J Clin Oncol. 1985;3:1246–50.

    PubMed  CAS  Google Scholar 

  209. Grunberg SM, Sonka S, Stevenson LL, Muggia FM. Progressive paresthesia after cessation of therapy with very high-dose cisplatin. Cancer Chemother Pharmacol. 1989;25:62–4.

    Article  PubMed  CAS  Google Scholar 

  210. Mollman JE, Hogan WM, Glover DJ, McCluskey LF. Unusual presentation of cis-platinum neuropathy. Neurology. 1988;38:488–90.

    Article  PubMed  CAS  Google Scholar 

  211. Tutsch KD, Arzoomanian RZ, Alberti D, et al. Phase I trial and pharmacokinetic study of ormaplatin. Proc Am Assoc Cancer Res. 1992;33:536.

    Google Scholar 

  212. Raymond E, Chaney SG, Taamma A, Cvitkovic E. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol. 1998;9:1053–71.

    Article  PubMed  CAS  Google Scholar 

  213. Milla P, Airoldi M, Weber G, Drescher A, Jaehde U, Cattel L. Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: effect on oxaliplatin pharmacokinetics, Pt-DNA adduct formation, and neurotoxicity. Anti-Cancer Drugs. 2009;20:396–402.

    Article  PubMed  CAS  Google Scholar 

  214. Cavaletti G, Bogliun G, Zincone A, Marzorati L, Melzi P, Frattola L, et al. Neuro- and ototoxicity of high-dose carboplatin treatment in poor prognosis ovarian cancer patients. Anticancer Res. 1998;18(5B):3797–802.

    PubMed  CAS  Google Scholar 

  215. Cavaletti G, Fabbrica D, Minoia C, Frattola L, Tredici G. Carboplatin toxic effects on the peripheral nervous system of the rat. Ann Oncol. 1998;9:443–7.

    Article  PubMed  CAS  Google Scholar 

  216. Konings PNM, Makkink WK, van Delft AML, Ruigt GSF. Reversal by NGF of cytostatic drug-induced reduction of neurite outgrowth in rat dorsal root ganglia in vitro. Brain Res. 1994;640:195–204.

    Article  PubMed  CAS  Google Scholar 

  217. Malgrange B, Delrée P, Rigo JM, Baron H, Moonen G. Image analysis of neuritic regeneration by adult rat dorsal root ganglion neurons in culture: quantification of the neurotoxicity of anticancer agents and of its prevention by nerve growth factor or basic fibroblast growth factor but not brain-derived neurotrophic factor or neurotrophin-3. J Neurosci Methods. 1994;53:111–22.

    Article  PubMed  CAS  Google Scholar 

  218. Hayakawa K, Sobue G, Itoh T, Mitsuma T. Nerve growth factor prevents neurotoxic effects of cisplatin, vincristine and taxol, on adult rat sympathetic ganglion explants in vitro. Life Sci. 1994;55:519–25.

    Article  PubMed  CAS  Google Scholar 

  219. Hayakawa K, Itoh T, Niwa H, Mutoh T, Sobue G. NGF prevention of neurotoxicity induced by cisplatin, vincristine and taxol depends on toxicity of each drug and NGF treatment schedule: in vitro study of adult rat sympathetic ganglion explants. Brain Res. 1998;794:313–19.

    Article  PubMed  CAS  Google Scholar 

  220. Geldof AA. Nerve-growth-factor-dependent neurite outgrowth assay; a research model for chemotherapy-induced neuropathy. J Cancer Res Clin Oncol. 1995;121:657–60.

    Article  PubMed  CAS  Google Scholar 

  221. Zheng JL, Stewart RR, Gao WQ. Neurotrophin-4/5 enhances survival of cultured spiral ganglion neurons and protects them from cisplatin neurotoxicity. J Neurosci. 1995;15:5079–87.

    PubMed  CAS  Google Scholar 

  222. Zheng JL, Stewart RR, Gao W-Q. Neurotrophin-4/5, brain-derived neurotrophic factor, and neurotrophin-3 promote survival of ­cultured vestibular ganglion neurons and protect them against neurotoxicity of ototoxins. J Neurobiol. 1995;28:330–40.

    Article  PubMed  CAS  Google Scholar 

  223. Gao W-Q, Dybdal N, Shinsky N, Murnane A, Schmelzer C, Siegel M, et al. Neurotrophin-3 reverses experimental cisplatin-induced peripheral sensory neuropathy. Ann Neurol. 1995;38:30–7.

    Article  PubMed  CAS  Google Scholar 

  224. Albers JW, Chaudhry V, Cavaletti G, Donehower RC. Interventions for preventing neuropathy caused by cisplatin and related ­compounds (Review). Copyright © 2011 The Cochrane Collaboration. Published by JohnWiley & Sons, Ltd.

    Google Scholar 

  225. Planting AS, Catimel G, de Mulder PH, de Graeff A, Hoppener F, Verweij J, et al. Randomized study of a short course of weekly cisplatin with or without amifostine in advanced head and neck cancer. EORTC Head and Neck Cooperative Group. Ann Oncol. 1999;10(6):693–700.

    Article  PubMed  CAS  Google Scholar 

  226. Kanat O, Evrensel T, Baran I, Coskun H, Zarifoglu M, Turan OF, et al. Protective effect of amifostine against toxicity of paclitaxel and carboplatin in non-small cell lung cancer: a single center ­randomized study. Medical Oncol. 2003;20(3):237–45.

    Article  CAS  Google Scholar 

  227. Lorusso D, Ferrandina G, Greggi S, Gadducci A, Pignata S, Tateo S, et al. Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients. Ann Oncol. 2003;14(7):1086–93.

    Article  PubMed  CAS  Google Scholar 

  228. Kemp G, Rose P, Lurain J, Berman M, Manetta A, Roullet B, et al. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol. 1996;14(7):2101–12.

    PubMed  CAS  Google Scholar 

  229. Bogliun G, Marzorati L, Marzola M, Miceli MD, Cantu MG, Cavaletti G. Neurotoxicity of cisplatin +/− reduced glutathione in the first-line treatment of advanced ovarian cancer. Int J Gynecol Cancer. 1996;6(5):415–19.

    Article  Google Scholar 

  230. Cascinu S, Cordella L, Del FE, Fronzoni M, Catalano G. Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double blind placebo-controlled trial. J Clin Oncol. 1995;13(1):26–32.

    PubMed  CAS  Google Scholar 

  231. Cascinu S, Catalano V, Cordella L, Labianca R, Giordani P, Baldelli AM, et al. Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2002;20(16):3478–83.

    Article  PubMed  CAS  Google Scholar 

  232. Milla P, Airoldi M, Weber G, Drescher A, Jaehde U, Cattel L. Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: effect on oxaliplatin pharmacokinetics, Pt-DNA adduct formation, and neurotoxicity. Anticancer Drugs. 2009;20(5):396–402.

    Article  PubMed  CAS  Google Scholar 

  233. Schmidinger M, Budinsky AC, Wenzel C, Piribauer M, Brix R, Kautzky M, et al. Glutathione in the prevention of cisplatin induced toxicities: a prospectively randomized pilot trial in patients with head and neck cancer and non small cell lung cancer. Wien Klin Wochenschr. 2000;112(14):617–23.

    PubMed  CAS  Google Scholar 

  234. Smyth JF, Bowman A, Perren T, Wilkinson P, Prescott RJ, Quinn KJ, et al. Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: results of a double-blind, randomised trial. Ann Oncol. 1997;8(6):569–73.

    Article  PubMed  CAS  Google Scholar 

  235. Hovestadt A, van der Burg ME, Verbiest HB, van Putten WL, Vecht CJ. The course of neuropathy after cessation of cisplatin treatment, combined with Org 2766 or placebo. J Neurol. 1992;239(3):143–6.

    Article  PubMed  CAS  Google Scholar 

  236. Van-der-Hoop RG, Vecht CJ, van-der-Burg ME, Elderson A, Oogerd W, Heimans JJ, et al. Prevention of cisplatin neurotoxicity with an ACTH(4–9) analogue in patients with ovarian cancer. N Engl J Med. 1990;322(2):89–94.

    Article  PubMed  CAS  Google Scholar 

  237. Van-Gerven JMA, Hovestadt A, Moll JW, Rodenburg CJ, Splinter A, van-Oosterom AT, et al. The effects of an ACTH (4–9) analogue n development of cisplatin neuropathy in testicular cancer: a randomized trial. J Neurol. 1994;241(7):432–5.

    Article  PubMed  CAS  Google Scholar 

  238. Roberts JA, Jenison EL, Kim K, Clarke-Pearson D, Langleben A. A randomized, multicenter, double-blind, placebo-controlled, dose-finding study of ORG 2766 in the prevention or delay of cisplatin-induced neuropathies in women with ovarian cancer. Gynecol Oncol. 1997;67(2):172–7.

    Article  PubMed  CAS  Google Scholar 

  239. Lin PC, Lee MY, Wang WS, Yen CC, Chao TC, Hsiao LT, et al. N-acetylcysteine has neuroprotective effects against oxaliplatin-based adjuvant chemotherapy in colon cancer patients: preliminary data. Support Care Cancer. 2006;14:484–7.

    Article  PubMed  Google Scholar 

  240. Gandara DR, Nahhas WA, Adelson MD, Lichtman SM, Podczaski ES, Yanovich S, et al. Randomized placebo-controlled multicenter evaluation of diethyldithiocarbamate for chemoprotection against cisplatin-induced toxicities. J Clin Oncol. 1995;13(2):490–6.

    PubMed  CAS  Google Scholar 

  241. Ishibashi K, Okada N, Miyazaki T, Sano M, Ishida H. Effect of calcium and magnesium on neurotoxicity and blood platinum ­concentrations in patients receiving mFOLFOX6 therapy: a ­prospective randomized study. Int J Clin Oncol. 2010;15(1):82–7.

    Article  PubMed  CAS  Google Scholar 

  242. Argyriou AA, Chroni E, Polychronopoulos P, Iconomou G, Koutras A, Makatsoris T, et al. Efficacy of oxcarbazepine for ­prophylaxis against cumulative oxaliplatin-induced neuropathy. Neurology. 2006;67:2253–5.

    Article  PubMed  CAS  Google Scholar 

  243. Argyriou AA, Chroni E, Koutras A, Iconomou G, Papapetropoulos S, Polychronopoulos P, et al. A randomized controlled trial ­evaluating the efficacy and safety of vitamin E supplementation for protection against cisplatin-induced peripheral neuropathy: final results. Support Care Cancer. 2006;14:1134–40.

    Article  PubMed  Google Scholar 

  244. Pace A, Savarese A, Picardo M, Maresca V, Pacetti U, Del MG, et al. Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy. J Clin Oncol. 2003;21(5):927–31.

    Article  PubMed  CAS  Google Scholar 

  245. Windebank AJ, Taylor BV. Neurological manifestations of vitamin B6 deficiency. In: Goetz CG, Aminoff MJ, editors. Handbook of clinical neurology: systemic diseases, Part II. New York: Elsevier Science, B. V; 1999. p. 423–37.

    Google Scholar 

  246. Wintrobe MM, Follis Jr RH, Miller MH, Stein HJ, Alcayaga R, Humphreys S, et al. Pyridoxine deficiency in swine with particular reference to anemia, epileptiform convulsions, and fatty liver. Bull John Hopkins Hosp. 1943;72:1–25.

    CAS  Google Scholar 

  247. Krinke G, Schaumburg HH, Spencer PS, Suter J, Thomann P, Hess R. Pyridoxine megavitaminosis produces degeneration of peripheral sensory neurons (sensory neuronopathy) in the dog. Neurotoxicology. 1980;2:13–24.

    Google Scholar 

  248. Berger AR, Schaumburg HH, Schroeder C, Apfel S, Reynolds R. Dose response, coasting, and differential fiber vulnerability in human toxic neuropathy: a prospective study of pyridoxine neurotoxicity. Neurology. 1992;42:1367–70.

    Article  PubMed  CAS  Google Scholar 

  249. Windebank AJ. Neurotoxicity of pyridoxine analogs is related to coenzyme structure. Neurochem Pathol. 1985;3:159–67.

    Article  PubMed  CAS  Google Scholar 

  250. Albin RL, Albers JW, Greenberg HS, Townsend JB, Lynn RB, Burke Jr JM, et al. Acute sensory neuropathy-neuronopathy from pyridoxine overdose. Neurology. 1987;37:1729–32.

    Article  PubMed  CAS  Google Scholar 

  251. Albin RL, Albers JW. Long-term follow-up of pyridoxine-induced acute sensory neuropathy-neuronopathy. Neurology. 1990;40:1319.

    Article  PubMed  CAS  Google Scholar 

  252. Chattopadhyay M, Wolfe D, Huang S, Goss J, Glorioso JC, Mata M, et al. In vivo gene therapy for pyridoxine-induced neuropathy by herpes simplex virus–mediated gene transfer of neurotrophin-3. Ann Neurol. 2002;51:19–27.

    Article  PubMed  CAS  Google Scholar 

  253. Helgren ME, Cliffer KD, Torrento K, Cavnor C, Curtis R, DiStefano PS, et al. Neurotrophin-3 administration attenuates deficits of pyridoxine-induced large fiber sensory neuropathy. J Neurosci. 1997;17:372–82.

    PubMed  CAS  Google Scholar 

  254. Rance NE, McArthur JC, Cornblath DR, Landstrom DL, Griffin JW, Price DL. Gracile tract degeneration in patients with sensory neuropathy and AIDS. Neurology. 1988;38(2):265–71.

    Article  PubMed  CAS  Google Scholar 

  255. Ulrich J. Morphological basis of Adie’s syndrome. Eur Neurol. 1980;19:390–5.

    Article  PubMed  CAS  Google Scholar 

  256. Egashira Y, Matsuyama H. Subacute myelo-optico-neuropathy (SMON) in Japan. With special reference to the autopsy cases. Acta Pathol Jpn. 1982;32 Suppl 1Suppl 1:101–16.

    PubMed  Google Scholar 

  257. Biemond A. Les degenerations spino-cerebelleuses. Folia Psychiatr Neurol Et Neurochir Neerl. 1951;54:216–23.

    CAS  Google Scholar 

  258. Biemond A. Hereditary posterior column ataxia. In: Vinken PJ, Bruyn GW, editors. Handbook of clinical neurology. New York: Elsevier; 1975. p. 377–81.

    Google Scholar 

  259. Singh N, Mehta M, Roy S. Familial posterior column ataxia (Biemond’s) with scoliosis. Eur Neurol. 1973;10:160–7.

    Article  PubMed  CAS  Google Scholar 

  260. Nachmanoff DB, Segal RA, Dawson DM, Brown RB, De Girolami U. Hereditary ataxia with sensory neuronopathy:Biemond’s ataxia. Neurology. 1997;48:273–5.

    Article  PubMed  CAS  Google Scholar 

  261. Hellenbroich Y, Bubel S, Pawlack H, Opitz S, Vieregge P, Schwinger E, et al. Refinement of the spinocerebellar ataxia type 4 locus in a large German family and exclusion of CAG repeat expansions in this region. J Neurol. 2003;250:668–71.

    Article  PubMed  CAS  Google Scholar 

  262. Edener U, Bernard V, Hellenbroich Y, Gillessen-Kaesbach G, Zuhlke C. Two dominantly inherited ataxias linked to chromosome 16q22.1: SCA4 and SCA31 are not allelic. J Neurol. 2011;258(7):1223–7.

    Article  PubMed  Google Scholar 

  263. Brown MJ, Martin JR, Asbury AK. Painful diabetic neuropathy. A morphometric study. Arch Neurol. 1976;33(3):164–71.

    Article  PubMed  CAS  Google Scholar 

  264. Goldblatt S. Pallhypesthesia: depression of the appreciation of vibration in trauma and in disease; a preliminary report. Arch Neurol Psychiatry. 1948;59:292.

    Article  PubMed  CAS  Google Scholar 

  265. Thomas PK, Walker JG. Xanthomatous neuropathy in primary ­biliary cirrhosis. Brain. 1965;88(5):1079–88.

    Article  PubMed  CAS  Google Scholar 

  266. Thomas PK, Hollinrake K, Lascelles RG, O’Sullivan DJ, Baillod RA, Moorhead JF, et al. The polyneuropathy of chronic renal ­failure. Brain. 1971;94:761–80.

    Article  PubMed  CAS  Google Scholar 

  267. Dastur DK. Cutaneous nerve in leprosy; the relationship between histopathology and cutaneous sensibility. Brain. 1955;78:615.

    Article  PubMed  CAS  Google Scholar 

  268. Halperin J, Luft BJ, Volkman DJ, Dattwyler RJ. Lyme neuroborreliosis. Peripheral nervous system manifestations. Brain. 1990;113(Pt 4):1207–21.

    Article  PubMed  Google Scholar 

  269. Smith IS, Kahn SN, Lacey BW, King RHM, Eames RA, Whybrew DJ, et al. Chronic demyelinating neuropathy associated with benign IgM paraproteinaemia. Brain. 1983;106:169–95.

    Article  PubMed  Google Scholar 

  270. Dyck PJ, Benstead TJ, Conn DL, Stevens JC, Windebank AJ, Low PA. Nonsystemic vasculitic neuropathy. Brain. 1987;110:843–53.

    Article  PubMed  Google Scholar 

  271. Kocen RS, Thomas PK. Peripheral nerve involvement in Fabry’s disease. Arch Neurol. 1970;22(1):81–8.

    Article  PubMed  CAS  Google Scholar 

  272. Hicks EP. Hereditary perforating ulcer of the foot. Lancet. 1922;1:319.

    Article  Google Scholar 

  273. Ogryzlo MA. A familial peripheral neuropathy of unknown etiology resembling Morvan’s disease. Can Med Assoc J. 1946;54:547.

    Google Scholar 

  274. Swanson AG. Congenital insensitivity to pain with anhidrosis. Arch Neurol. 1963;8:299.

    Article  PubMed  CAS  Google Scholar 

  275. Low PA, Burke WJ, McLeod JG. Congenital sensory neuropathy with selective loss of small myelinated fibers. Ann Neurol. 1978;3(2):179–82.

    Article  PubMed  CAS  Google Scholar 

  276. Sobue G, Nakao N, Murakami K, Yasuda T, Sahashi K, Mitsuma T, et al. Type I familial amyloid polyneuropathy. A pathological study of the peripheral nervous system. Brain. 1990;113:903–19.

    Article  PubMed  Google Scholar 

  277. Blok MJ, Van den Bosch BJ, Jongen E, Hendrickx A, Die-Smulders CE, Hoogendijk JE, et al. The unfolding clinical spectrum of POLG mutations. Med Genet. 2009;46:776–85.

    Article  CAS  Google Scholar 

  278. Schulte C, Synofzik M, Gasser T, Schols L. Ataxia with ophthalmoplegia or sensory neuropathy is frequently caused by POLG mutations. Neurology. 2009;73:898–902.

    Article  PubMed  Google Scholar 

  279. Milone M, Benarroch EE, Wong LJ. POLG-related disorders. Defects of the nuclear and mitochondrial genome interaction. Neurology. 2011;77:1847–52.

    Article  PubMed  Google Scholar 

  280. Le Quesne PM, McLeod JG. Peripheral neuropathy following a single exposure to arsenic. Clinical course in four patients with electrophysiological and histological studies. J Neurol Sci. 1977;32:437–51.

    Article  PubMed  Google Scholar 

  281. Goldstein NP, Jones PH, Brown JR. Peripheral neuropathy after exposure to an ester of dichlorophenoxyacetic acid. J Am Med Assoc. 1959;171:1306–9.

    Article  PubMed  CAS  Google Scholar 

  282. Schaumburg HH, Spencer PS. Human toxic neuropathy due to industrial agents. In: Dyck PJ, Thomas PK, Lambert EH, editors. Peripheral neuropathy. 2nd ed. Philadelphia: W. B. Saunders Company; 1984. p. 2115–32.

    Google Scholar 

  283. Gross JA, Haas ML, Swift TR. Ethylene oxide neurotoxicity: report of four cases and review of the literature. Neurology. 1979;29:978–83.

    Article  PubMed  CAS  Google Scholar 

  284. Katrak SM, Pollock M, O’Brien CP, Nukada H, Allpress S, Calder C, et al. Clinical and morphological features of gold neuropathy. Brain. 1980;103:671–93.

    Article  PubMed  CAS  Google Scholar 

  285. Spencer PS, Couri D, Schaumburg HH. n-hexane and methyl n-butyl ketone. In: Spencer PS, Schaumburg HH, editors. Experimental and clinical neurotoxicology. 1st ed. Baltimore: Williams & Wilkins; 1980. p. 456–75.

    Google Scholar 

  286. Biehl JP, Nimitz HJ. Studies on the use of a high dose of isoniazid. I. Toxicity studies. Am Rev Tuberc Pulm Dis. 1954;70:430–41.

    CAS  Google Scholar 

  287. Wasserman TH, Phillips TL, Van Raalte G, Urtasun R, Partington J, Koziol D, et al. The neurotoxicity of misonidazole: potential modifying role of phenytoin sodium and dexamethasone. Br J Radiol. 1980;53(626):172–3.

    Article  PubMed  CAS  Google Scholar 

  288. Lovelace RE, Horwitz SJ. Peripheral neuropathy in long-term diphenylhydantoin therapy. Arch Neurol. 1968;18:69–77.

    Article  PubMed  CAS  Google Scholar 

  289. Murai Y, Kuroiwa Y. Peripheral neuropathy in chlorobiphenyl poisoning. Neurology. 1971;21:1173–6.

    Article  PubMed  CAS  Google Scholar 

  290. Prosser PR, Karam JH. Diabetes mellitus following rodenticide ingestion in man. JAMA. 1978;239(12):1148–50.

    Article  PubMed  CAS  Google Scholar 

  291. Cavanagh JB, Fuller NH, Johnson HRM, Rudge P. The effects of thallium salts, with particular reference to the nervous system changes. A report of three cases. Q J Med. 1974;43:293–319.

    PubMed  CAS  Google Scholar 

  292. Smith BE, Dyck PJ. Peripheral neuropathy in the eosinophilia-myalgia syndrome associated with l-tryptophan ingestion. Neurology. 1990;40:1035–40.

    Article  PubMed  CAS  Google Scholar 

  293. Casey EB, Jellife AM, Le Quesne PM, Millett YL. Vincristine neuropathy. Clinical and electrophysiological observations. Brain. 1973;96:69–86.

    Article  PubMed  CAS  Google Scholar 

  294. Willison HJ, O’Leary CP, Veitch J, Blumhardt LD, Busby M, Donaghy M, et al. The clinical and laboratory features of chronic sensory ataxic neuropathy with anti-disialosyl IgM antibodies. Brain. 2001;124:1968–77.

    Article  PubMed  CAS  Google Scholar 

  295. Cho ES, Spencer PS, Jorther BS, Schaumburg HH. A single intravenous injection of doxorubicin (Adriamycin) induces sensory neuronopathy in rats. Neurotoxicology. 1980;1:583.

    CAS  Google Scholar 

  296. Johnson PC. Hematogenous metastases of carcinoma to dorsal root ganglia. Acta Neuropathol (Berlin). 1977;38(2):171–2.

    Article  CAS  Google Scholar 

  297. Davison C, Balser BH. Myeloma and its neural complications. Arch Surg. 1937;35:913.

    Article  Google Scholar 

  298. Dickerman RC, Chason JL. Alterations in the dorsal root ganglia and adjacent nerves in the leukemias, the lymphomas, and multiple myeloma. Am J Pathol. 1958;34:349.

    Google Scholar 

  299. Russell DS, Rubinstein LJ. Pathology of tumours of the nervous system. 4th ed. Edinburgh: Edward Arnold Ltd.; 1977. p. 356.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. EMG Laboratory, 3B, Mayo School of Graduate Medical Education, Mayo Clinic, 13400 East Shea Boulevard, Scottsdale, AZ, 85259, USA

    Ales Hlubocky MD

  2. EMG Laboratory, 3B, Mayo Medical School, Mayo Clinic, 13400 East Shea Boulevard, Scottsdale, AZ, 85259, USA

    Benn E. Smith MD

Authors
  1. Ales Hlubocky MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Benn E. Smith MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ales Hlubocky MD .

Editor information

Editors and Affiliations

  1. School of Medicine Department of Neurology, University Hospitals Case Medical Center Case Western Reserve University, Cleveland, Ohio, USA

    Bashar Katirji

  2. Department of Neurology, George Washington University, Washington, District of Columbia, USA

    Henry J. Kaminski

  3. University School of Medicine Department of Neurology, Louis Stokes Cleveland VA Medical Center Case Western Reserve, Cleveland, Ohio, USA

    Robert L. Ruff

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media New York

About this chapter

Cite this chapter

Hlubocky, A., Smith, B.E. (2014). Dorsal Root Ganglion Disorders. In: Katirji, B., Kaminski, H., Ruff, R. (eds) Neuromuscular Disorders in Clinical Practice. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-6567-6_23

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-6567-6_23

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-6566-9

  • Online ISBN: 978-1-4614-6567-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation